You are viewing the site in preview mode
Skip to main content
Characteristics
Mean (SD) or proportion
HR (95% credible interval)
Age at index date (years)
69.573 (10.939)
1.036 (1.028, 1.045)
Male (%)
52.075%
1.220 (1.022, 1.474)
Duration of diabetes at index date (years)
9.647 (1.112)
0.935 (0.867, 1.040)
aDCSI (score)
2.296 (1.856)
1.211 (1.170, 1.255)
Second-line glucose-lowering agent at index date (%)
Sulfonylurea
65.347%
(ref.)
Acarbose
10.907%
0.921 (0.682, 1.192)
Dipeptidyl-peptidase 4 inhibitor
10.714%
0.670 (0.514, 0.942)
Meglitinide
8.639%
1.733 (1.436, 2.170)
Thiazolidinedione
4.393%
1.116 (0.713, 1.703)
Comorbidities and diabetes-related complications within 1 year before index date (%)
Hypertension
77.703%
1.279 (1.031, 1.595)
Dyslipidemia
42.568%
0.786 (0.647, 0.908)
Retinopathy
32.288%
1.142 (0.971, 1.321)
Nephropathy
13.851%
1.392 (1.056, 1.703)
Neuropathy
17.905%
0.899 (0.710, 1.079)
Peripheral vascular disease
9.846%
1.301 (0.968, 1.658)
CVD-related medications within 1 year before index date (%)
Lipid-modifying agent
43.243%
0.939 (0.781, 1.112)
α-blocker
8.929%
1.090 (0.806, 1.445)
β-blocker
48.069%
1.172 (1.005, 1.343)
Renin-angiotensin-aldosterone agent
52.027%
1.194 (0.973, 1.408)
Diuretics
28.427%
1.941 (1.638, 2.282)
Calcium channel blocker
58.832%
1.074 (0.912, 1.259)
Antiarrhythmic
6.129%
1.459 (1.131, 1.822)
Cardiac glycoside
4.778%
2.962 (2.277, 3.859)
Vasodilator
29.054%
2.352 (2.000, 2.742)
Antiplatelet agent
69.932%
1.166 (0.984, 1.397)
Anticoagulant
2.799%
2.104 (1.468, 3.298)
Monthly concentrations of air pollutants during the follow-up
CO (ppm)
0.501 (0.170)
3.791 (1.945, 8.088)
NO (ppb)
5.446 (4.026)
1.088 (1.032, 1.129)
NO2 (ppb)
17.320 (5.628)
1.120 (1.079, 1.166)
NOx (ppb)
22.603 (8.993)
1.066 (1.046, 1.093)
O3 (ppb)
27.767 (4.648)
1.024 (0.984, 1.073)
PM10 (μg/m3 )
54.506 (17.207)
1.052 (1.028, 1.070)
PM2.5 (μg/m3 )
31.294 (9.425)
1.105 (1.080, 1.135)
SO2 (ppb)
3.876 (1.527)
2.095 (1.738, 2.352)
Abbreviations : SD Standard deviation, aDCSI adapted Diabetes Complication Severity Index, CVD Cardiovascular disease
Index date refers to the date of the beginning of second-line glucose-lowering agent therapy